All In Biotech

Drug Trial Radar · NCT01957735

BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors

A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

97

Actual

Start

Oct 2013

Primary completion

Feb 1, 2017

Study completion Feb 1, 2017

Sponsor

Lead sponsor
BPGbioIndustry
Sponsor type
Industry
First posted
Oct 8, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous intravenous (IV) infusion as monotherapy(treatment Arm 1) and in combination with chemotherapy (treatment Arm 2) in patients with solid tumors.

Conditions

  • Metastatic Cancer
  • Cancer
  • Solid Tumor

Interventions

  • BP31510 monotherapyDrug

  • BP31510 in combination with chemotherapyDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine Maximum Tolerated Dose (MTD) of BP31510Time frame: Wach week of treatment for the duration of Cycle 1 up to 4 weeks on Arm 1 and 6 weeks for Arm 2

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Palo Alto Medical Foundation

    Sunnyvale, California

  • Weill Cornell Solid Tumor Oncology Practice

    New York, New York

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.